FDA Finds Ingredient's IND Past After Signing Off For Supplement Use
This article was originally published in The Rose Sheet
Executive Summary
Supplement industry stakeholders say FDA makes an unjustifiable regulatory move by stating that the widely used dietary supplement ingredient is noncompliant, while the finding compels the agency to reverse its earlier acceptance of NDI notifications for vinpocetine.